It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumor tissues consist of heterogeneous cells that originate from stem cells; however, their cell fate determination program remains incompletely understood. Using patient-derived organoids established from patients with advanced colorectal cancer (CRC), we evaluated the potential of olfactomedin 4 (OLFM4)+ stem cells to produce a bifurcated lineage of progenies with absorptive and secretory properties. In the early phases of organoid reconstruction, OLFM4+ cells preferentially gave rise to secretory cells. Additionally, we found that Paneth-like cells, which do not exist in the normal colon, were induced in response to Notch signaling inhibition. Video recordings of single OLFM4+ cells revealed that organoids containing Paneth-like cells were effectively propagated and that their selective ablation led to organoid collapse. In tumor tissues, Paneth-like cells were identified only in the region where tumor cells lost cell adhesion. These findings indicate that Paneth-like cells are directly produced by OLFM4+ stem cells and that their interaction contributes to tumor formation by providing niche factors. This study reveals the importance of the cell fate specification program for building a complete tumor cellular ecosystem, which might be targeted with novel therapeutics.
An analysis of the reconstitution process of orgenoids revelaed that OLFM4+ cells in colorectal cancer directrly generate Paneth-like cells, which supported OLFM4+ cells growth by providing niche.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Cancer Institute, Japanese Foundation for Cancer Research, Department of Cell Biology, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
2 Cancer Institute, Japanese Foundation for Cancer Research, Department of Cell Biology, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Kyoto University, Department of Surgery, Graduate School of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
3 Cancer Institute, Japanese Foundation for Cancer Research, Department of Cell Biology, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Yale School of Medicine, Child Study Center, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
4 The University of Tokyo, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, Kashiwa, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
5 Kyoto University, Department of Surgery, Graduate School of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
6 Cancer Institute, Japanese Foundation for Cancer Research, Department of Cell Biology, Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Kyoto University, Department of Surgery, Graduate School of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033); Uji-Tokushukai Medical Center, Department of Surgery, Kyoto, Japan (GRID:grid.258799.8)